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The aim of this work was to investigate the distribu-
tion of 5-methoxypsoralen in the skin after oral
administration of the drug and to examine the cor-
relation between skin and plasma concentrations. 5-
Methoxypsoralen skin concentration was measured
in both healthy and psoriatic sites of 10 psoriatic
patients after single and multiple oral doses. The
results obtained show that 5-methoxypsoralen accu-
mulates at higher levels in the more external layers
of the skin after oral administration. The high af®n-
ity of drug for the stratum corneum was con®rmed
by in vitro skin af®nity measurements. The concen-
tration of 5-methoxypsoralen in the skin was similar
in both psoriatic and healthy sites, indicating that the
pathology does not in¯uence drug distribution in the
skin. After single dose administration, a linear correl-
ation was found between skin and plasma drug con-
centration. After multiple dose administration, drug
concentration in the skin was fairly constant despite
the variable plasma concentrations in different sub-
jects. Key words: photochemotheray/psoriasis/PUVA
therapy/tissue distribution. J Invest Dermatol 117:379±382,
2001
P
hotochemotherapy with 5-methoxypsoralen (5-MOP,
Bergapten) plus ultraviolet A light irradiation (PUVA) is
an effective treatment for several skin diseases, such as
psoriasis, vitiligo, and lichen planus (McNeely and Goa,
1998). Moreover, PUVA is effective in the treatment of
the T cell lymphoma (Mycosis fungoides) (Zackheim, 1999). In the
skin, PUVA produces several species of free radicals and cross-links
in DNA (McNeely and Goa, 1998), responsible for its ef®cacy
against vitiligo and psoriasis, respectively.
The standard protocol of the British Photodermatology Group
(British Photodermatology Group, 1994) recommends the admin-
istration of an oral dose of 1.2 mg per kg of 5-MOP 3 h before
UVA irradiation. This time interval allows the drug to reach the
skin, after absorption and distribution, where it can reach a level
useful for its therapeutic activity.
After oral administration, however, 5-MOP blood concentration
showed a certain inter- and intraindividual variability (Stolk et al,
1981; Treffel et al, 1992; Tanew et al, 1998; Shephard et al, 1999).
In order to monitor the amount of drug in the skin at the time of
UVA exposure, the interstitial ¯uid concentration of 5-MOP given
orally was measured, using the skin blister ¯uid technique
(Humbert et al, 1991; Treffel et al, 1992). Depending on the time
of blister formation, 5-MOP concentration in skin blister ¯uid was
25%±50% of plasma concentration. Additionally, it has been
shown, in vitro, that 5-MOP binds to epidermis (Artuc et al,
1979) and to stratum corneum keratin (Prognon et al, 1985),
suggesting the possibility of higher tissue concentration compared
with plasma. For these reasons, the direct knowledge of skin 5-
MOP concentration could give important suggestions for the
dermatology practice.
The purpose of this work was to measure 5-MOP skin
content in healthy and diseased sites of psoriatic patients after
oral single and multiple administration. Drug concentration
pro®le was determined in the epidermis and dermis, and the
existence of a correlation between skin and plasma concentra-
tion was checked.
MATERIALS AND METHODS
5-MOP and trimethyl psoralen (TMP) were obtained from Galeno s.r.l.
(Prato, Italy). 5-MOP capsules were prepared in pharmacy using maize
starch, lactose, magnesium stearate, and silicon dioxide as excipients.
All chemicals used were of analytical grade.
Experimental protocol Ten psoriatic patients (seven man and three
women, age range 30±60 y; mean initial Psoriasis Area Severity Index
(PASI) of 17 6 8) were enrolled in this study and gave informed
authorization. The research followed the tenets of the Declaration of
Helsinki (1964) and was approved by the human experimentation
committee of the University of Parma.
Because 5-MOP oral bioavailability depends on circadian rhythms
(Treffel et al, 1990), the patients were instructed to take the drug in the
morning, with a low fat breakfast. 5-MOP was given as capsules, at the
dose of 1.2 mg per kg (mean amount administered 89 6 12 mg), 3 h
before UVA irradiation.
A blood sample and a skin punch biopsy were taken just before UVA
irradiation. After the ®rst PUVA session, therapy continued two times
per week for a total of eight sessions. After the last session, a blood
sample and a skin biopsy were again taken.
5-MOP analysis The skin biopsies (4 mm in diameter and 1 mm in
thickness) were immediately frozen in liquid nitrogen and 20 mm thick
slices, parallel to the skin surface, were obtained, using a cryomicrotome
(Miles, Elkhart, IN) (Volpato et al, 1997). The total thickness analyzed
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was 400 mm, corresponding to stratum corneum, epidermis, and part of
the dermis.
5-MOP was extracted from each skin slice with 400 ml of methanol
(containing trimethyl psoralen 0.5 mg per ml as internal standard),
vortexing occasionally for 20 min at room temperature. After the
addition of 100 ml of water and centrifugation at 11 000 3 g for 20 min,
the solution was ®ltered through a 0.45 mm nylon ®lter (Lida, Kenosha,
WI).
The drug was quantitated using reverse-phase high-performance liquid
chromatography (HPLC). The isocratic HPLC system (LC 250 pump,
Perkin Elmer, Norwalk, CT) was equipped with an UV detector
(wavelength 300 nm) and a C18 reversed phase column (Nova-Paká 3.9
‘ 150 mm Waters, Milford, MA). The mobile phase was methanol-
water (65:35) at a ¯ow rate of 0.8 ml per min. The retention times of 5-
MOP and TMP were 3.5 and 8 min, respectively.
The analytical method was validated according to the USP24±System
suitability. The limit of quanti®cation of the assay was 0.05 ng per ml,
with a relative standard deviation of 2.9%. The tailing factor was
1.35 6 0.14 and the theoretical plates were 1197. The recoveries of 5-
MOP and TMP, from blank skin slices spiked with known amounts of
5-MOP and extracted according to the previously described procedure,
were 91.0 6 2.3 and 88.2 6 4.3%, respectively.
Blood samples were collected in heparinized test tubes and centrifuged
at 700 3 g for 10 min. A sample of plasma (100 ml) was sonicated with
400 ml of methanol containing TMP 0.5 mg per ml as internal standard.
One hundred microliters of water were added and the mixture was
centrifuged at 11 000 3 g for 20 min. The supernatant was ®ltered
through a 0.45 mm nylon ®lter and analyzed by HPLC as reported
before, using methanol-water 55:45 as mobile phase. This eluent allowed
the separation of 5-MOP peak from the interfering peaks derived from
plasma. The validation parameters did not change signi®cantly.
Drug af®nity for skin slices Skin slices obtained from patients not
previously treated with 5-MOP, were used to measure in vitro af®nity of
5-MOP for the skin (Hikima and Tojo, 1997). Each slice (area 0.6 cm2,
thickness 20 mm) was equilibrated with 300 ml of a 0.430 mg per ml
water solution of 5-MOP for 2 h. Then, the residual concentration of
drug in the aqueous phase was measured by HPLC. The concentration
of 5-MOP into each skin slice, considered as an expression of af®nity,
was calculated as the difference between initial and ®nal drug
concentration in the aqueous phase, taking 1.2 3 10±3 cm3 as the
volume of each skin slice.
Statistical analysis The signi®cance of the differences between the
values of 5-MOP recovered in the skin was assessed using a test for the
comparison of means of related samples (paired-sample, two sided t test).
The correlation between skin and plasma concentration was performed
by linear regression, using the least-square method and evaluating the
signi®cance of slope and intercept. Both analyzes were performed using
Microsoft Excel 8.0 software running on a Macintosh PowerBook G3.
RESULTS AND DISCUSSION
5-MOP skin distribution was studied by measuring its content in
20 mm thick skin slices, as a function of the distance from the
surface. Biopsies of normal and diseased skin of the same patients
were taken 3 h after oral intake of 5-MOP capsules.
In healthy skin, drug content was higher in the external slices and
decreased exponentially from the stratum corneum towards the
dermis (Fig 1a). This drug pro®le was unexpected, considering
that 5-MOP was administered orally and reached the skin from the
systemic circulation, i.e., from dermal capillaries. Nevertheless,
there are reports in the literature indicating that 5-MOP has strong
af®nity for skin proteins in vitro (Artuc et al, 1979; Prognon et al,
1985). Similarly, a higher concentration of ¯uconazole was found
in the stratum corneum compared with the epidermis and the
dermis after oral administration in man (Wildfeuer et al, 1994) and
similar results were obtained with TMP (Ros et al, 1988). In
conclusion, this result with 5-MOP is due to the reported high
af®nity of the drug for the skin
The shape of 5-MOP content pro®les in psoriatic skin was quite
similar, indicating that drug distribution in skin layers was almost
independent of the presence of the psoriatic lesion. A small
difference between healthy and psoriatic sites, though not statis-
tically signi®cant, was observed in the range 50±150 mm of depth,
where 5-MOP was present at higher concentrations in diseased
skin. This small difference could be attributed to increased blood
¯ow and thickness in psoriatic skin compared with normal skin
(Hern et al, 1999).
After multiple dose administration (twice a week oral adminis-
tration, 1 mo of therapy; Fig 1b), the pro®le obtained in healthy
skin was practically superimposed to the one obtained in psoriatic
skin. Comparing the distribution of 5-MOP in the skin after
multiple and single administration, an increase of the amount of
drug recovered in the epidermal portion of the skin (0±200 mm
from the skin surface), in particular for healthy skin, was found;
however, the level of signi®cance of the difference between single
and multiple doses was not particularly high (p on average 0.3), due
to the large variability of the values.
5-MOP plasma concentration at the time of biopsy (3 h after ®rst
dosing) was 378 6 161 ng per ml (mean 6 SD), in agreement with
the data reported in the literature (Stolk et al, 1981; Treffel et al,
1992; Tanew et al, 1998; Shephard et al, 1999). The average value
of plasma concentration obtained after multiple dose administration
was practically the same, namely 370 6 233 ng per ml (mean
6 SD). This result indicated that the drug did not accumulate in
blood after multiple administration, in agreement with the short
plasma elimination half-life (45±105 min according to Stolk et al,
1981; 192 min according to Treffel et al, 1992).
The total amount of 5-MOP present in the skin was
estimated from the amount in the skin biopsy (area 0.1256 cm2)
multiplied for an average body surface area of 1.8 m2. The
percentage of 5-MOP present in the skin was 59 6 15% of the
dose administered 3 h after single administration and 66 6 13%
Figure 1. 5-MOP skin content after oral administration. 5-MOP
skin content was obtained after oral single administration (a) and after
multiple administration (b) at the dose of 1.2 mg per kg as capsules, in
healthy (full symbols) and psoriatic (open symbols) sites of 10 patients
(mean values 6 SD, n = 10). Each data point represents the average drug
content in each skin slice, cut at 20 mm thickness from a 4 mm diameter
biopsy.
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after multiple administration. Because more than 50% of the
administered dose reached the skin 3 h after administration, skin
uptake was very rapid.
In order to study the correlation between 5-MOP skin and
plasma concentration at the time of biopsy, the amounts of drug
recovered in each skin slice were cumulated and transformed in
concentration. A linear correlation between skin and plasma
concentration at the time of biopsy was found after the ®rst
administration (Fig 2). The slope of the regression line was
signi®cantly different from zero (mean value 6 con®dence interval
95%: 137.9 6 52.9) whereas the intercept was not signi®cantly
different from zero (mean value 6 con®dence interval 95%:
22.1 6 21.3). 5-MOP skin concentration signi®cantly increased as
the plasma concentration increased, indicating an uptake by the
skin from the blood compartment.
Multiple administration determined a not signi®cant ¯uctuation
of skin concentration from 60 and 100 mg per cm3, for plasma
concentration varying from 0.05 to 0.75 mg per cm3. The resulting
regression equation showed intercept signi®cantly different from
zero (mean value 6 con®dence interval 95%: 74.6 6 16.5) and
slope not signi®cantly different from zero (mean value 6 con®-
dence interval 95%: 16.2 6 39.8).
In conclusion, the concentration of 5-MOP in the skin was
higher than in plasma, after both single and multiple administra-
tions. After multiple administration, the skin content was less
dependent on plasma concentration. These results are quite
interesting, but due to the limited number of time points taken
between the two administrations should be considered as
preliminar.
There are indications in the literature that 5-MOP binds to the
epidermis (Artuc et al, 1979) and to stratum corneum keratin
(Prognon et al, 1985). To con®rm this result, we checked the
af®nity of 5-MOP for the skin slices, by measuring in vitro the
uptake of individual slices from an aqueous solution. Blank skin
slices were equilibrated with a water solution of 5-MOP at a
concentration of 430 ng per ml (in the range of plasma concen-
trations). 5-MOP showed strong af®nity for the ®rst skin slice for
which the concentration found was 50±100 times higher than the
concentration in aqueous solution. The uptake progressively
decreased going into the epidermis, to reach an average value of
about 5 mg per cm3 in the dermis; however, these results indicate a
lower af®nity for the skin compared with those obtained by Artuc
et al (1979) and to our in vivo experiments, in which the ratio skin
to plasma concentration was on average 200. The result can be
justi®ed considering the relatively short equilibration time (2 h)
used in the af®nity experiments and/or by the fact that the skin was
frozen before use.
Because skin distribution data obtained in this work support a
long drug half-life in the skin, much longer than in plasma, four
additional patients received 5-MOP orally (1.2 mg per kg) and skin
biopsies of healthy sites were taken 3 h after administration. Three
days later, before the following drug administration, a second
biopsy was taken. The results obtained (Fig 3) show that the
concentration pro®le in the skin was practically unchanged 3 d after
the last administration compared with the ®rst biopsy, even if
plasma concentration was undetectable in all patients. This
experiment suggests a very low clearance of 5-MOP from the
epidermal tissue, even if due to the limited number of patients
analyzed the statistical signi®cance is limited.
CONCLUSION
From the results obtained it can be concluded that 5-MOP
accumulates in the skin after oral administration. The concentration
in the skin decreased going from the stratum corneum towards the
dermis. The concentration of 5-MOP in the skin was the same in
both psoriatic and healthy sites, indicating that the pathology does
not in¯uence drug skin distribution. 5-MOP skin distribution was
not largely different after single and multiple drug administration.
5-MOP skin content was practically the same 3 h and 3 d after a
single oral administration, indicating a low clearance of the drug
from the skin. It is perhaps necessary, however, to increase the
number of time points in order to con®rm the time kinetics
through all the layers of the skin.
The linear correlation resulting between skin drug content and
plasma concentration after ®rst dose administration, and the absence
of correlation found after multiple administration, indicates that a
stable level of 5-MOP in the skin is reached after multiple
administration. The higher af®nity of the drug for the skin
compared with plasma, limits the ¯uctuations of skin concentration
in response to variations of plasma concentration.
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